We came across a bullish thesis on Sarepta Therapeutics (SRPT) on X (formerly Twittter) by user quantumup. In this article we will summarize the bulls’ thesis on SRPT. Year-to-date, Sarepta Therapeutics (SRPT) stock gained 51% and on July 29th it had a closing price of $146.03.
Scientist in a lab working on a research project, focusing on biotechnology and healthcare advancements.
Sarepta Therapeutics (SRPT) is a leading biopharmaceutical company specializing in the development of precision genetic medicines to treat rare diseases. With a strong focus on Duchenne muscular dystrophy (DMD), Sarepta’s innovative therapies aim to improve patient outcomes and transform the standard of care for individuals with serious genetic disorders.
RBC Capital has upgraded Sarepta Therapeutics (SRPT) to Outperform with a target price of $182. Despite initial concerns over treatment throughput, center capacity, and manufacturing supply for Elevidys, RBC believes these issues are overstated. They conducted a physician survey and gathered feedback from a major DMD advocacy group, which bolstered their confidence in Elevidys’ launch potential. RBC expects significant near-term growth and views the current stock price as an attractive buying opportunity ahead of a major launch.
Piper Sandler has also noted increased investor interest in SRPT following Elevidys’ expanded FDA approval on June 20th. While shares have declined by about 8% since the approval, the sales trajectory from the broader label remains a key factor for investor sentiment. Piper Sandler attended the PPMD Annual Meeting, where experts and DMD families expressed significant interest in Elevidys. Both ambulatory and non-ambulatory patients are interested, and experts discussed the necessary steps to ensure equitable access to the treatment.
Overall, the bull thesis on SRPT is driven by the anticipated successful launch of Elevidys, bolstered by favorable feedback from medical professionals and advocacy groups, along with significant patient interest.
READ NEXT: Analyst Sees a New $25 Billion “Opportunity” for NVIDIA and 10 Best of Breed Stocks to Buy For The Third Quarter of 2024 According to Bank of America.
This article is originally published at Insider Monkey.
Hedge Fund Resource Center